One serum blood test is sufficient to diagnose hyperprolactinemia, and dynamic testing of prolactin secretion should be avoided, according to new guidelines published in the February issue of the Journal of Clinical Endocrinology & Metabolism.
MONDAY, Feb 21 (HealthDay News)-One serum blood test is sufficient to diagnose hyperprolactinemia, and dynamic testing of prolactin secretion should be avoided, according to new guidelines published in the February issue of the Journal of Clinical Endocrinology & Metabolism.
Shlomo Melmed, MD, from the Cedars Sinai Medical Center in Los Angeles, and Endocrine Society colleagues used the GRADE system-grading of recommendations, assessment, development, and evaluation-to analyze recommendations and level of evidence. Clinical practice guidelines for diagnosis and treatment of hyperprolactinemia were reviewed.
The guidelines recommend a single measurement of serum prolactin to diagnose hyperprolactinemia, with a level above the normal limit confirming diagnosis. Dynamic testing of prolactin secretion is not recommended. Following diagnosis, the cause should be established by excluding medication use and pituitary and parasellar tumors. In suspected drug-induced hyperprolactinemia, the drug should be discontinued or replaced. In patients with symptomatic prolactin-secreting microadenomas or macroadenomas, dopamine agonist therapy, preferably cabergoline, can reduce prolactin levels and treat other symptoms. For symptomatic patients whose prolactin levels cannot be reduced, the guidelines suggest increasing the medication before referring a patient for surgery. Pregnant women should discontinue dopamine agonist therapy as soon as possible, and should avoid serum prolactin measurements.
"Testing for hyperprolactinemia is straightforward, owing to the ease of ordering a serum prolactin measurement. Accordingly, an evidence-based, cost-effective approach to management of this relatively common endocrine disorder is required," the authors write.
Several authors disclosed financial relationships with pharmaceutical and medical device companies, including Pfizer and Novartis.
AbstractFull Text (subscription or payment may be required)
Related Content
Cesarean deliveries linked to reduced fecundability and increased infertility risk
June 27th 2024A recent study found that women with multiple children and a history of cesarean deliveries face lower fecundability and higher infertility risks compared to those with vaginal deliveries.
Read More
S1E4: Dr. Kristina Adams-Waldorf: Pandemics, pathogens and perseverance
July 16th 2020This episode of Pap Talk by Contemporary OB/GYN features an interview with Dr. Kristina Adams-Waldorf, Professor in the Department of Obstetrics and Gynecology and Adjunct Professor in Global Health at the University of Washington (UW) School of Medicine in Seattle.
Listen
Similar delivery times between misoprostol dosages among obese patients reported
May 29th 2024A recent study found that obese patients undergoing induction of labor experienced similar delivery times regardless of whether they received 50 μg or 25 μg of vaginal misoprostol, though multiparous patients showed faster delivery with the higher dosage.
Read More
Buprenorphine use in pregnancy linked to decreased fetal breathing movements
May 18th 2024According to a poster presented at ACOG 2024, use of the synthetic opioid buprenorphine depressed fetal breathing in biophysical profile assessments, but had no significant impact on other factors like amniotic fluid index or fetal tone.
Read More